Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)

NCT04135794 | Active Not Recruiting

• 1 other identifier: 19-5843
• Study Type: observational
• Target: 377
• Locations: 1 country
• Sites: 1

Brief Summary

This study is being done to help further understand how MR-guided adaptive RT in conjunction with the Integrated Magnetic Resonance Linear Accelerator (MRL) can improve patient outcomes. This study will include participants who will be receiving radiotherapy using the MRL machine to target their cancer more precisely. Participants will be asked to have a few extra MR scans taken during their RT planning and to complete a few quality of life questionnaires.

Conditions

Cancer

Keywords

MRL

Outcome Measures

Primary Outcomes (3)

• Local, regional and distant tumor control rates

  Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.

  Up to 5 years post-radiotherapy

• Disease-free and overall survival rates

  Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.

  Up to 5 years post-radiotherapy

• Complication rates measured using the Common Toxicity Criteria for Adverse Events

  Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.

  Within 3 months of completing treatment

Secondary Outcomes (4)

• Patient experience and anxiety related to MR imaging and adaptive RT with the MR

  Immediately after first MRL treatment visit

• Patient experience and anxiety related to MR imaging and adaptive RT with the MR

  Immediately after last MRL treatment visit

• Patient experience and anxiety related to MR imaging and adaptive RT with the MR

  d prior to starting treatment with the MRL, immediately after the last MRL treatment, at the first follow-up visit and annually thereafter during follow-up (up to 5 years post treatment)

• Patient experience and anxiety related to MR imaging and adaptive RT with the MR

  each ambulatory care and radiation treatment review clinic visit (up to 5 years post treatment)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with cancer from any clinical site requiring radiotherapy

You may qualify if:

• Patients 18 years or older with a diagnosis of cancer, regardless of clinical site or stage
• Planned to receive a course of MR-guided adaptive RT using the MRL
• Ability to provide informed consent

You may not qualify if:

• Patients under 18 years old

Sponsors & Collaborators

• University Health Network, Toronto: lead

Study Sites (1)

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

Location

MeSH Terms

Conditions

Neoplasms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 15, 2019
• First Posted: October 23, 2019
• Study Start: December 9, 2019
• Primary Completion (Estimated): November 30, 2027
• Study Completion (Estimated): November 30, 2027
• Last Updated: March 5, 2026

Record last verified: 2026-03

Locations

CA (1)